Structure−Guided Optimization of Niclosamide Derivatives as Direct STAT3 Inhibitors Targeting a Novel Binding Site
Preprint
- 14 July 2025
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
Signal transducer and activator of transcription 3 (STAT3), a key oncogenic driver activated in approximately 70% of cancers, represents a highly attractive therapeutic target. Although various inhibitors of the STAT3 pathway have been developed, none directly target the STAT3 protein, and no FDA-approved STAT3 inhibitors are currently available. In this study, we identified a novel binding site for niclosamide on STAT3 using X-ray crystallography, revealing unique interactions spanning the coiled-coil, DNA-binding, and linker domains. Niclosamide was shown to disrupt STAT3-DNA binding with an IC₅₀ value of 219 ± 43.4 μM, as determined by fluorescence polarization (FP) assays. We synthesized a library of over 45 niclosamide analogues. Among this expanded set of compounds, MQ021 inhibited STAT3-DNA binding by 60% at a concentration of 100 μM, comparable to the 40% inhibition observed with niclosamide. Microscale thermophoresis (MST) assays confirmed the comparable activity of the compound 21 (Kd = 155 ± 59 μM) relative to niclosamide (Kd = 281 ± 55 μM). These results offer insights into the structure–activity relationships (SAR) of niclosamide derivatives and provide a foundation for the development of STAT3-targeted therapeutics for cancer treatment that exploit this new binding site.Keywords
All Related Versions
This publication has 35 references indexed in Scilit:
- Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosisEuropean Journal of Medicinal Chemistry, 2018
- Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicityBioorganic & Medicinal Chemistry, 2017
- Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorptionEuropean Journal of Medicinal Chemistry, 2016
- Structure–activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposureBioorganic & Medicinal Chemistry, 2015
- Discovery of 5-(2′,4′-difluorophenyl)-salicylanilides as new inhibitors of receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesisEuropean Journal of Medicinal Chemistry, 2015
- Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2014
- Structure–activity relationships of antitubercular salicylanilides consistent with disruption of the proton gradient via proton shuttlingBioorganic & Medicinal Chemistry, 2013
- Synthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analoguesEuropean Journal of Medicinal Chemistry, 2012
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- ChemInform Abstract: New Groups of Antimycobacterial Agents: 6-Chloro-3-phenyl-4-thioxo-2H-1,3-benzoxazine-2(3H)-ones and 6-Chloro-3-phenyl-2H-1,3-benzoxazine-2,4(3H)-dithiones.ChemInform, 2000